CARLOS DZIK

(Fonte: Lattes)
Índice h a partir de 2011
6
Lattes
Projetos de Pesquisa
Unidades Organizacionais
LIM/60 - Laboratório de Imunologia Clínica e Alergia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2018 ×

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • article 3 Citação(ões) na Scopus
    Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
    (2018) VELHO, Pedro Isaacsson; NARDO, Mirella; SOUZA, Manoel Carlos Leonardde Azevedo; BONADIO, Renata R. C. Colombo; MARTA, Guilherrne Nader; MUNIZ, David Q. B.; BASTOS, Diogo Assed; DZIK, Carlos
    Purpose Sunitinib and pazopanib are multitargeted tyrosine kinase inhibitors (TKIs) that act against vascular endothelial growth factor receptors and are standard first-line treatment options for metastatic clear cell renal cell carcinoma (ccRCC). The Brazilian public health system diverges from the randomized clinical trials in the availability of first and subsequent lines of treatment and in clinical and demographic characteristics of patients. Therefore, it is essential to describe the history of advanced ccRCC during and after TKI treatment in this population. Methods We performed a retrospective analysis of patients with advanced ccRCC treated with a first-line TKI (either sunitinib or pazopanib) between February 2009 and March 2017 in a single academic Brazilian cancer center (Instituto do Cancer do Estado de Sao Paulo). Results Of the 222 patients, 109 were treated with sunitinib and 113 with pazopanib. The median duration of treatment and overall survival (OS) were 6.4 and 15.2 months for sunitinib and 6.7 and 14.2 months for pazopanib, respectively. Discontinuation of treatment occurred secondarily to progressive disease or death in 64.2% of patients using sunitinib and in 54.8% of patients using pazopanib. Adverse events were responsible for discontinuation of treatment in 28.4% of patients in the sunitinib group and in 22.1% in the pazopanib group. According to Memorial Sloan-Kettering Cancer Center risk categories, the OS was 32.9 months, 15.9 months, and 8.1 months for low risk, intermediate risk, and poor risk, respectively (hazard ratio, 1.72; 95% CI, 1.13 to 2.26; P < .001). ConclusionThe use of TKI inhibitors as first-line treatment of metastatic RCC is effective and feasible in the Brazilian public health. However, the median OS of our population is considerably lower compared with the prospective trials that evaluated the same drugs. (C) 2018 by American Society of Clinical Oncology
  • conferenceObject
    Performance status (PS) in advanced germ cell tumors (aGCT): Clinical and prognostic value of an underreported important variable.
    (2018) VASCONCELLOS, Vitor Fiorin de; BASTOS, Diogo Assed; PEREIRA, Allan Andresson Lima; PEREIRA, Bruno Rodriguez; SILVA, Jamile Almeida; MUNIZ, David Queiroz Borges; GUGLIELMETTI, Giuliano; NAHAS, William Carlos; DZIK, Carlos
  • conferenceObject
    Tumor mutational burden (TMB), intratumoral genetic heterogeneity (ITGH) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).
    (2018) BASTOS, Diogo Assed; LIMA, Mariana; MATTEDI, Romulo Loss; DZIK, Carlos; RIBEIRO-FILHO, Leopoldo; CORDEIRO, Mauricio; NAHAS, William Carlos; SOUZA, Jussara Michaloski; AMANO, Mariane; BETTONI, Fabiana; BUZATTO, Vanessa; SANTOS, Filipe Ferreira dos; BARREIRO, Rodrigo; GALANTE, Pedro Alexandre Favoretto; CAMARGO, Anamaria Aranha
  • conferenceObject
    Clinical characteristics and treatment outcomes of patients (pts) with advanced germ cell tumor (aGCT) treated at a tertiary cancer center in Brazil.
    (2018) VASCONCELLOS, Vitor Fiorin de; BASTOS, Diogo Assed; PEREIRA, Allan Andresson Lima; PEREIRA, Bruno Rodriguez; SILVA, Jamile Almeida; MUNIZ, David Queiroz Borges; GUGLIELMETTI, Giuliano; NAHAS, William Carlos; DZIK, Carlos